Diabetic Macular Edema
Conditions
Brief summary
The goal of this study is to evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in diabetic macular edema (DME) patients.
Detailed description
The study included patients who were being observed in the retina departments of 8 tertiary hospitals in the Northern Marmara Region of Turkey (Istanbul's Asian Side, Kocaeli, and Sakarya). The records of DME patients treated with an anti-VEGF agent between January 2015 and December 2018 were reviewed.
Interventions
OTHERRetrospective study
Retrospective study
Sponsors
Kocaeli University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Inclusion criteria
* Diabetic macular edema treated with intravitreal anti-VEGF injection * Having at least 4 or more annual examination visits
Exclusion criteria
* Phacoemulsification surgery in the last 1 month * PRFK / grid / focal / micropulse in the last 4 months * Previous intraocular surgery (excluding PPV and phacoemulsification)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visit and Intravitreal Injection Numbers | First year | The primary outcomes were changes in best-corrected visual acuity and central macular thickness in the first year and frequency of visits and intravitreal anti-VEGF injections. |
Countries
Turkey (Türkiye)
Outcome results
None listed